Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
NCT04705831
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Post-Viral Fatigue Syndrome
Post-Viral Disorder (Disorder)
Covid19
Interventions
DRUG:
Ruconest
Sponsor
IMMUNOe Research Centers